SG10201901676UA - Pyrazolothiazole compound and medicine comprising same - Google Patents
Pyrazolothiazole compound and medicine comprising sameInfo
- Publication number
- SG10201901676UA SG10201901676UA SG10201901676UA SG10201901676UA SG10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA SG 10201901676U A SG10201901676U A SG 10201901676UA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- medicine
- same
- effect
- pyrazolothiazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME The invention provides a pyrazolothiazolecompound compound of the formula [IJ, or a pharmaceutically 5 acceptable salt thereof: The compound of the invention has JAKI inhibitory activity, and thus, irr~unosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the 10 treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp. Figure for publication: None
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014177969 | 2014-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201901676UA true SG10201901676UA (en) | 2019-03-28 |
Family
ID=55439874
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701447UA SG11201701447UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
SG10201901676UA SG10201901676UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701447UA SG11201701447UA (en) | 2014-09-02 | 2015-09-02 | Pyrazolothiazole compound and medicine comprising same |
Country Status (33)
Country | Link |
---|---|
US (2) | US9937176B2 (en) |
EP (1) | EP3190116B1 (en) |
JP (1) | JP6558372B2 (en) |
KR (1) | KR102294330B1 (en) |
CN (1) | CN107108653B (en) |
AU (1) | AU2015312886B2 (en) |
BR (1) | BR112017003800B1 (en) |
CA (1) | CA2959721C (en) |
CL (1) | CL2017000478A1 (en) |
CO (1) | CO2017002982A2 (en) |
CY (1) | CY1123320T1 (en) |
DK (1) | DK3190116T3 (en) |
ES (1) | ES2827243T3 (en) |
HR (1) | HRP20201382T1 (en) |
HU (1) | HUE050565T2 (en) |
IL (1) | IL250729B (en) |
LT (1) | LT3190116T (en) |
MA (1) | MA40605B1 (en) |
MX (1) | MX2017002488A (en) |
MY (1) | MY181814A (en) |
NZ (1) | NZ729494A (en) |
PE (1) | PE20170668A1 (en) |
PH (1) | PH12017500383B1 (en) |
PL (1) | PL3190116T3 (en) |
PT (1) | PT3190116T (en) |
RS (1) | RS60798B1 (en) |
RU (1) | RU2688660C2 (en) |
SG (2) | SG11201701447UA (en) |
SI (1) | SI3190116T1 (en) |
TW (1) | TWI679205B (en) |
UA (1) | UA121869C2 (en) |
WO (1) | WO2016035814A1 (en) |
ZA (1) | ZA201701492B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
TWI712604B (en) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | Crystal of compound with JAK inhibitory effect |
US11167953B2 (en) | 2017-06-09 | 2021-11-09 | Mitsubishi Electric Corporation | Passenger conveyor |
CN115135316A (en) * | 2019-12-23 | 2022-09-30 | 思研(Sri)国际顾问与咨询公司 | Lipoxygenase inhibitors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3600390A1 (en) | 1986-01-09 | 1987-07-16 | Hoechst Ag | DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME |
US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
US20070225333A1 (en) | 2004-04-28 | 2007-09-27 | Bryans Justin S | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor |
CA2623032A1 (en) * | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
NZ592990A (en) * | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
BRPI0722364A2 (en) | 2006-01-17 | 2011-08-16 | Vertex Pharma | azaindoles, pharmaceutical composition and uses of said compounds |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
CN102007133B (en) * | 2008-04-15 | 2013-06-12 | 卫材R&D管理有限公司 | 3-phenylpyrazolo[5,1-b]thiazole compounds |
JO3041B1 (en) | 2008-07-25 | 2016-09-05 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
ES2422263T3 (en) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Bicyclic pyrazoles as protein kinase inhibitors |
TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
JP5739446B2 (en) | 2009-12-18 | 2015-06-24 | ファイザー・インク | Pyrrolo [2,3-d] pyrimidine compound |
TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
JP2011136925A (en) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
BR112012017269A2 (en) | 2010-01-12 | 2016-05-03 | Hoffmann La Roche | tricyclic heterocyclic compounds, compositions and methods of use thereof |
UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
EP2616443A1 (en) | 2010-09-14 | 2013-07-24 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
WO2012054364A2 (en) | 2010-10-22 | 2012-04-26 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
TWI679205B (en) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | Pyrazolothiazole compounds and medicine |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/en active
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/en active
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/en active Active
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/en active Application Filing
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/en active Active
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/en unknown
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
- 2015-09-02 PT PT158384669T patent/PT3190116T/en unknown
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/en active
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 ES ES15838466T patent/ES2827243T3/en active Active
- 2015-09-02 RS RS20201081A patent/RS60798B1/en unknown
- 2015-09-02 UA UAA201702990A patent/UA121869C2/en unknown
- 2015-09-02 CA CA2959721A patent/CA2959721C/en active Active
- 2015-09-02 MX MX2017002488A patent/MX2017002488A/en unknown
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 MA MA40605A patent/MA40605B1/en unknown
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/en unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/en active Active
- 2015-09-02 SI SI201531340T patent/SI3190116T1/en unknown
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 PL PL15838466T patent/PL3190116T3/en unknown
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/en unknown
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/en active IP Right Grant
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/en active IP Right Grant
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/en unknown
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/en unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-08-31 HR HRP20201382TT patent/HRP20201382T1/en unknown
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123320T1 (en) | PYRAZOLOTHIAZOLE COMPOUND AND DRUG CONTAINING IT | |
PH12016502582A1 (en) | TrK-INHIBITING COMPOUND | |
CL2015002468A1 (en) | Processes and intermediates to make a jak inhibitor | |
IL255203B (en) | Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders | |
EA201891374A1 (en) | SUBSTITUTED 2-PHENYL-3- (PIPERAZINMETHIL) IMIDAZOPIRIDINES AND THEIR APPLICATION | |
WO2011084991A3 (en) | Fluorinated hdac inhibitors and uses thereof | |
EA201591269A1 (en) | METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | |
WO2014151456A3 (en) | Treatment of inflammatory diseases | |
IL283469A (en) | Inhalable compositions for use in the treatment of pulmonary diseases | |
EP3091959A4 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
EP4069847A4 (en) | Treatment of lower airways disorders | |
EP3937937A4 (en) | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine | |
MX2022013014A (en) | New crystalline forms of vilanterol trifenatate and processes for their preparation. | |
EA201790072A1 (en) | DERIVATIVES 2-ARYL-4-HYDROXY-1,3-TIAZOLE FOR USE AS TRPM8 INHIBITORS IN THE TREATMENT OF NEURALGIA, PAIN, CHRONIC OBSTRUCTIVE LUNG AND ASTHMA | |
Fokkens | Phenotyping, endotyping and clinical decision-making | |
MX2018010334A (en) | Crystal of compound having jak-inhibiting activity. | |
EP3534713A4 (en) | Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases | |
MX2019014773A (en) | Ccl2 inhibitors. | |
GB201802353D0 (en) | Treatment of chronic obstructive pulmonary disease | |
GB201802354D0 (en) | Treatment of chronic obstructive pulmonary disease | |
MX2016001747A (en) | Diphenylox. | |
MX2015016549A (en) | Combination of oxymetazoline and ipratropium in topical nasal application for the cough treatment. | |
TH1701001056A (en) | Pyrazolothiazole and its medicinal compounds include them. |